title: Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
abstract: Interactions between CD40 and its ligand, CD154 (CD40L, gp39), have been shown to play a central role in the regulation of humoral immunity. Recent evidence suggests that this ligand-receptor pair also plays an important role in the induction of cell-mediated immune responses, including those directed against viral pathogens, intracellular parasites, and alloantigens. The contribution of this ligand-receptor pair to the development of protective immunity against syngeneic tumors was evaluated by blocking the in vivo function of CD154 or by studying tumor resistance in mice genetically deficient in CD40 expression (CD40-/-). In the former case, anti-CD154 monoclonal antibody treatment inhibited the generation of protective immune responses after the administration of three potent tumor vaccines: irradiated MCA 105, MCA 105 admixed with Corynebacterium parvum adjuvant, and irradiated B16 melanoma cells transduced with the gene for granulocyte macrophage colony-stimulating factor. Confirmation of the role of CD40/CD154 interactions in tumor immunity was provided by the overt tumor susceptibility in CD40-deficient mice as compared to that in CD40+/+ mice. In this case, wild-type but not CD40-deficient mice could be readily protected against live TS/A tumor challenge by preimmunization with TS/A admixed with C. parvum. These findings suggest a critical role for CD40/CD154 interactions in the induction of cellular immunity by tumor vaccines and may have important implications for future approaches to cell-based cancer therapies.
authors.affiliation: Department of Microbiology, Dartmouth Medical School and Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Mackey
authors.forename: J R
authors.initials: JR
authors.lastname: Gunn
authors.forename: P P
authors.initials: PP
authors.lastname: Ting
authors.forename: H
authors.initials: H
authors.lastname: Kikutani
authors.forename: G
authors.initials: G
authors.lastname: Dranoff
authors.forename: R J
authors.initials: RJ
authors.lastname: Noelle
authors.forename: R J
authors.initials: RJ
authors.lastname: Barth
mesh_terms: D000276:Adjuvants, Immunologic / Q000502:physiology; D000818:Animals; D019013:CD40 Antigens / Q000502:physiology*; D023201:CD40 Ligand; D019496:Cancer Vaccines / Q000276:immunology*; D005260:Female; D007111:Immunity, Cellular / Q000502:physiology; D008562:Membrane Glycoproteins / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015996:Survival Rate; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D019013:CD40 Antigens; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; D023201:CD40 Ligand